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ABSTRACT
Breast cancer is one of the most common malignancies among woman. Decades of scientific study have linked the 
overexpression of ERBB2 antigen to aggressive tumors. To target aggressive breast cancer, chimeric antigen receptor 
(CAR) technology can be utilized. For this, human T-cells are transduced with a gene sequence encoding a CAR that is 
specific for tumor-associated antigens (TAAs). These genetically-engineered CAR transduced T-cells (CAR-T cells) are 
able to target the tumor antigen without the need for major histocompatibility complex (MHC) recognition, rendering 
it a potentially universal immunotherapeutic option. However, efficient transduction of therapeutic gene into human 
T-cells and further cell expansion are challenging. In this study, we reported a successful optimization of a transduction 
protocol using spinoculation on CD3+ T-cells with different concentrations of lentiviral plasmid encoding the CAR gene. 
CD3+T-cells were isolated from the peripheral blood mononuclear cells (PBMCs). The constructed CAR gene was inserted 
into a lentiviral plasmid containing the green fluorescent protein (GFP) tag and lentiviral particles were produced. These 
lentiviral particles were used to transduce activated T-cells by spinoculation. T-cells were activated using Dynabead-
conjugated CD3/CD28 human  T-cell activator  and interleukin-2 (IL-2) before transduction. CD3+ T-cells were selected 
and GFP expression, which indicated transduction, was observed. Future studies will focus on in vitro and in vivo models 
to determine the efficiency of CAR-T cells in specifically targeting ERBB2-expressing cells. 
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ABSTRAK
Kanser payudara adalah salah satu kanser yang kerap melanda kaum wanita. Kajian saintifik telah mengaitkan lebihan 
ekspresi antigen ERBB2 pada barah kanser yang lebih agresif. Untuk menangani masalah ini, teknologi reseptor kimera 
antigen (CAR) boleh digunakan. Untuk ini, sel T manusia ditransduksi dengan urutan gen pengekodan CAR yang khusus 
untuk antigen berkaitan-barah (TAA). Sel T yang ditransduksi dengan CAR (CAR-T) secara genetik dapat mensasar kepada 
antigen kanser tanpa memerlukan pengenalan kompleks kehistoserasian utama (MHC), menjadikan ia pilihan terapi 
imun berpotensi umum. Walau bagaimanapun, transduksi gen terapeutik ke dalam sel T manusia dan pengembangan 
sel selanjutnya adalah mencabar. Dalam kajian ini, kami berjaya melaporkan pengoptimuman protokol transduksi 
menggunakan spinokulasi sel T CD3+ dengan kepekatan plasmid lentiviral pengekodan gen CAR yang berbeza. Sel T 
CD3+ telah diasingkan daripada sel-sel mononuklear darah periferi (PBMCs). Gen CAR yang dibina dimasukkan ke dalam 
plasmid lentiviral mengandungi protein pendarfluor hijau (GFP) dan zarah lentiviral penuh dihasilkan. Zarah lentiviral 
digunakan untuk transduksi spinokulasi T-sel yang telah diaktifkan. Sel T diaktifkan menggunakan CD3 berkonjugasi 
Dynabead/pengaktif manusia sel T CD28 dan interleukin-2 (IL-2) sebelum transduksi. Kejayaan transduksi dilaporkan 
apabila ekspresi GFP diperhatikan di dalam sel T CD3+. Kajian masa depan akan memberi tumpuan kepada model in 
vitro dan in vivo untuk menentukan kecekapan sel CAR-T dalam mensasarkan dan membunuh sel kanser yang mempunyai 
ekpresi ERBB2 berlebihan.
Kata kunci: Kanser payudara; reseptor kimera antigen (CAR); sel CD3+ T; terapi imuno
INTRODUCTION
T-cells of the immune system can eradicate disease at 
extreme specificity by identifying the antigen expressed by 
the antigen presenting cells (Maher 2012). T-cell receptors 
(TCRs) present on the T-cells engage antigens that are 
presented by the major histocompatibility complex (MHC) 
molecules (Maher 2012). In most inflammatory conditions, 
an adaptive immune response  is triggered  following the 
presentation of peptides (non-self) by MHC molecules to 
immune cells. However, during tumor progression, the 
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immune system often  perceives tumor antigens as ‘self’ 
rather than foreign, hence becomes tolerant to tumors 
(Whiteside 2010). 
 To overcome this challenge, researchers designed 
genetically-modified T-cells to specifically target the 
desired tumor-associated antigens (TAAs) (Jena et al. 
2010). The T-cells were equipped with a Chimeric Antigen 
Receptor (CAR). A CAR links an antigen specific single-
chain antibody fragment (scFv)  to intracellular signalling 
domains, CD28 and CD3-ζ chain of the T-cell receptor (TCR) 
(Porter et al. 2011). The scFv segment of the CAR is able 
to directly target and bind to the TAA on the tumor cells, 
bypassing the MHC immune recognition (Maher 2012). 
Thus, genetically-modified T-cells to express CAR retain 
its immunogenic functions against tumor cells.
 Human epidermal growth factor receptor 2 (ERBB2) is 
an antigen of interest for CAR technology because ERBB2 
overexpression in breast cancer (occurring in 15-25% of 
cases) (Iqbal & Iqbal 2014) is associated with increased 
tumor aggression, resistance to chemotherapeutics and 
ultimately poor patient prognosis (Eroles et al. 2012). 
ERBB2 overexpression is also observed in endometrial 
cancer (12% of cases) (Elsahwi & Santin 2011), gastric and 
esophageal cancer (15-20% of cases) (Iqbal & Iqbal 2014), 
in addition too varian (Teplinsky & Muggia 2015), stomach 
(Iqbal & Iqbal 2014), bladder (Iqbal & Iqbal 2014) and lung 
carcinomas (Iqbal & Iqbal 2014) (Figure 1). ERBB2 positive 
breast cancer patients are treated with anti-ERBB2 therapy 
in addition to surgery, chemotherapy and radiation (Carey 
2011). Treatment options for anti-ERBB2 therapies include 
the monoclonal antibodies trastuzumab and pertuzumab 
(Scott et al. 2012). Hormone therapies such as tamoxifen 
(Indah et al. 2015) and aromatase inhibitors (Dieci et al. 
2016) are also available. 
 Current clinical trials trend is moving towards 
immunotherapeutic strategies such as checkpoint inhibitors, 
oncolytic viruses and anti-ERBB2 intracellular single-
chain antibodies (Marchini et al. 2016). Novel avenues 
such as ERBB2-specific tyrosine kinase inhibitors (i.e. 
emodin) (Schroeder et al. 2014), ERBB2-targeting antisense 
oligonucleotides (Han et al. 2013) and rationally designed 
anti-ERBB2 peptide mimetics (Govindarajan et al. 2012) are 
also undergoing different stages of clinical trials (Figure 1). 
The limitations of chemotherapy and radiation include the 
fact that they not only affect cancerous cells, but also target 
all actively dividing healthy cells. This can lead to prominent 
side effects including loss of appetite, hair loss, nausea and 
vomiting, extreme fatigue, mouth soreness, bleeding and 
low immunity against infections (Carey 2011) (Figure 1). 
Thus, ERBB2 is a suitable TAA for use in CAR technology. 
 The genetic-modification of T-cells to express CAR 
involves the delivery of CAR gene via viral transduction 
into autologous human T-cells. A huge problem concerning 
T-cell manipulation involves the foremost step of isolating 
a pure population of T-cells from patient’s blood for use 
in immunotherapy (Stemberger et al. 2014). Previous 
studies adopting the CAR method have largely manipulated 
the CD8+ T-cells sub-population within the CD3+ T-cells 
(Jensen et al. 2010; Zhong et al. 2009). However, achieving 
clinically significant numbers via ex vivo expansion of this 
modified population of CD8+ T-cells are difficult (Maher 
2012). Furthermore, primary human T-cells  are resistant to 
transduction by virus, as naïve T-cells are non-proliferating 
or quiescent cells in vitro. CAR gene integration into the 
FIGURE 1. The schematic diagram portraying the trends of therapeutic options in ERBB2 overexpressing cancer: advantages and 
limitations. The diagram shows overexpression in multiple cancers, the current treatment options for ERBB2-positive cancers 
(breast cancer), and clinical trials for targeting ERBB2 with its limitations and advantages
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genome of the transduced T-cells will also require prior 
activation through the TCR and cytokines (Zack et al. 2013). 
In order to overcome the multitude of challenges involved 
in the CAR gene delivery into T-cells, we optimized a robust 
protocol for the fast and efficient transduction of CAR into 
human T-cells.
 In the current study, we aimed to optimize a 
transduction protocol to efficiently deliver CAR gene into 
human CD3+ T-cells. The CAR gene consists of an anti-
ERBB2 scFv extracellular domain followed by the CD8 
transmembrane domain and two co-stimulatory domains, 
namely, CD28 and CD3-ζ (ERBB2 scFv-CD8a-CD28-CD3-ζ).
This would be able to specifically target ERBB2 antigens 
on tumor cells with increased efficiency and reduced side 
effects.
MATERIAL AND METHODS
HUMAN T-CELLS CULTURE AND EXPANSION
Ten milliliters of collected blood samples from healthy 
donors (National Medical Research Register, Malaysia; 
ethical approval number: NMRR-14-587-20201) were 
processed to isolate peripheral blood mononuclear cells 
(PBMCs) by density gradient separation using Ficoll-Paque 
PLUS (1.077 g/mL, Amersham Biosciences, Sweden). 
Isolated human PBMCs were cultured in advanced RPMI 
1640 media (Gibco/Invitrogen, Massachusetts, USA), 
supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin (Pen/Strep), and 0.1% gentamycin 
at 37°C and 5% CO2 concentration. CD3+ cells were then 
isolated from PBMCs using an EasySep™ Human T Cell 
Enrichment Kit (Stem Cell Technologies,Vancouver, 
Canada) following manufacturer’s protocol. The isolated 
CD3+ T-cells in complete culture media were mixed with 
Dynabead-conjugated CD3/CD28 human T-cell activator 
(1:10 ratio) (Gibco/Invitrogen, Massachusetts, USA) and 
50 U/mL of interleukin-2 (IL-2) (PeproTech, Rocky Hill, 
USA) for activation. 
FLOW CYTOMETRIC ANALYSIS
To detect surface antigens, aliquots of cultured T-cells 
were washed twice with phosphate-buffered saline 
(PBS) (Gibco/Invitrogen; Massachusetts, USA), pH 
7.2 after centrifugation at 1000 × g for 5 min. The 
cells were incubated with fluorescein isothiocyanate 
(FITC), allophycocyanin (APC), phycoerythrin (PE) or 
phycoerythrin Cyanine7 (PE-Cy7) conjugated monoclonal 
antibodies on ice for 45 min. The antibodies used were CD3, 
CD4, CD8, CD25 and CD69, all purchased from Affymetrix 
eBioscience, Inc. (San Diego, USA). After incubation, 
the cells were washed twice by centrifugation at 300 × 
g for 5 min and subjected to flow cytometric analysis. In 
parallel, unstained and fluorochrome matched, non-specific 
isotype labeled cells were used as controls. The stained 
samples were assessed using BD FACS Canto II (Becton 
Dickinson (BD) BioSciences; New Jersey, USA). Gating 
at FACS acquisition was applied to exclude any dead cells 
and cell debris. Ten thousand events were acquired and 
the data from stained cells were acquired using FACSDiva 
6.1.3 software (Becton Dickinson (BD) BioSciences; New 
Jersey, USA). 
PLASMID CONSTRUCTION
pReceiver-Lv 183 lentiviral expression plasmid 
(GeneCopoeia Rockville, USA) containing a green 
fluorescent protein (GFP) selection marker located 
downstream of the inserted CAR target gene was used. The 
CAR gene was synthesized according to the WO2012031744 
(NCBI accession number: JB399738) patent number and 
consisted of 1515 bp.
LENTIVIRAL PARTICLE PRODUCTION
The Lenti-Pac™ HIV Expression Packaging Kit from 
GeneCopoeia (Rockville, MD, USA) was used in 
combination with the lentiviral expression plasmid 
(pReceiver-Lv 183) containing the CAR gene to produce 
complete viral particles. The lentiviral vectors were 
produced using the packaging  cell line, 293FT. A total of 
2.5 μg, 4.0 μg or  5.5 μg of lentiviral expression plasmid 
and 5.0 μL (0.5 μg/μL) of Lenti-Pac HIV mix were diluted 
in a sterile tube containing 200 μL of Opti-MEM® I (Gibco/
Invitrogen; Massachusetts, USA). In a separate tube, 15 
μL of EndoFectin Lenti reagent was diluted into 200 μL 
of Opti-MEM I. The diluted EndoFectin Lenti reagent was 
then mixed with the DNA solution before adding it to the 
293FT cells. Cells were then incubated in a CO2 incubator 
at 37°C. After 12 h, the overnight culture medium was 
replaced with fresh DMEM with 5% FBS and 1% Pen/
Strep. The pseudovirus-containing culture medium was 
collected at 48 h post-transfection. The supernatant 
was then concentrated using amicon viral concentration 
ultrafiltration 100 kDa tubes  (Merck Milipore; Darmstadt, 
Germany) with centrifugation at 1200 × g for 15 min at 
4°C. The freshly collected concentrated virus supernatant 
was used for transduction of T-cells. 
TRANSDUCTION OF CAR GENE INTO T-CELLS VIA 
LENTIVIRUS EXPRESSION SYSTEM
A total of 2 × 105 T-cells were plated on a 24-well plate 24 
h before viral infection. Viral media were prepared with 
0.5 mL of virus suspension diluted in complete medium 
with polybrene (8 μg/mL). The target CD3+ T-cells were 
infected by adding the viral media. For the control well, 0.5 
mL of complete medium with polybrene only was added. 
The cells were spinoculated at 800 × g for 1.5 h at 32°C. 
The plates were incubated overnight in a CO2 incubator. 
The culture media were replaced with fresh complete media 
(without polybrene) 12 h after transduction. The infected 
target T-cells were analyzed for transgene expression using 
the internal GFP control via fluorescence microscopy. 
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RESULTS
EFFICIENT ISOLATION OF CD3+ T-CELLS FROM HUMAN 
PBMCS USING MAGNETIC SELECTION
Fresh blood was collected and the PBMC layer was isolated 
by density gradient centrifugation. To further enhance the 
lymphocyte concentration for downstream experimental 
work, the PBMC layer was subjected to magnetic 
separation of CD3+ T-cells using the EasySep™ Human 
T Cell Enrichment Kit. Our results showed an increase 
in CD3+ T-cells after magnetic selection (Figure 2). The 
selection process was extremely efficient in enriching 
for a homogenous T-cells population by depleting all 
other PBMCs and as a result, the T-cells population was 
increased from 78.2% to 99.4%. The isolated CD3+ cells 
were activated for transduction and expansion.
SUCCESSFUL ACTIVATION OF ISOLATED CD3+ T-CELLS
Morphological observation of CD3+ T-cells showed 
that non-activated T-cells appeared as single spherical 
suspension in culture. Meanwhile, activated T-cells 
supplemented with Dynabead-conjugated CD3/CD28 
human T-cell activator and IL-2 appeared as clumped 
cells (Figure 3(A)). Figure 3(B) shows the flow 
cytometric analysis of T-cell activation. Non-activated 
CD3+ T-cells showed presence of 62.1% of CD4 and 
32.6% of CD8+ cells. The number of cells expressing 
CD25 and CD69 activation markers were 0.1% and 0.2%, 
respectively. Activation of CD3+ did not affect changes 
in the population of CD4 (65.1%) and CD8 cells (34.4%). 
However, the percentage of cells expressing of CD25 and 
CD69  activation markers have increased to 15.5% and 
14.7% (Figure 3(B)). This indicates that the activation 
protocol employed was successful in inducing activation 
of T-cell, priming them for efficient transduction. This 
result was consistent between variations in variables 
including the donor and passage of the cells (data not 
shown). All flow cytometry dot plots were compared to 
specific isotype controls.
PRODUCTION OF CAR LENTIVIRAL PARTICLES AND 
HUMAN T-CELL TRANSDUCTION
We transfected 293FT packaging cells using three different 
concentrations of the CAR transfer plasmid (2.5, 4.0 and 5.5 
μg) to produce lentivirus particles (Figure 4). From Figure 
4, we observed that GFP expression using 5.5 μg of the CAR 
transfer plasmid was visibly higher than that of 2.5 μg or 
4.0 μg of the CAR transfer plasmid in the 293FT cells 48 
h post-transfection. Following that, the supernatants were 
FIGURE 2. Immunophenotyping of peripheral blood mononuclear cells (PBMCs) pre- and post-CD3+ magnetic selection. Fresh 
PBMCs were subjected to CD3+ magnetic selection and immediately characterized by flow cytometry. An increase in CD3+ T-cells 
from 78.2% pre-magnetic selection to 99.4% post-magnetic selection was seen. CD3+ isotype-matched antibody was used as a 
negative control. All dot plots shown were gated from the lymphocyte population of the FSC-A vs. SSC-A plot
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FIGURE 3. Activation in T-cells by Dynabead-conjugated  CD3/CD28 human T-cell activator. (A) Morphological changes upon activation, 
(B) Flow cytometric analysis of T-cell activation surface markers. (A) Morphological observation of CD3+ T-cells: non-activated T-cells 
in culture appear as spherical shaped suspension cells while activated T-cells supplemented with Dynabead-conjugated  CD3/CD28 
human T-cell activator and IL-2 appear as darker clumped cells that formed suspension spheres, Figure 3(B) flow cytometric analysis 
of T-cell activation cell surface markers. Isotype control of flow cytometry results indicated for surface markers CD4, CD8, CD25 and 
CD69, showing 0.0%. Non-activated T-cells showed T-cell markers such as CD4 (62.1%) and CD8 (32.6%) while activation markers CD25 
(0.1%) and CD69 (0.2%) are negative. Activated T-cells showed T-cell markers such as CD4 (65.1%), CD8 (34.4%) and activation markers 
CD25 (15.5%) and CD69  (14.7%) are shown to be significantly increased compared to the non-activated T-cells. All flow cytometry dot 
plots were compared to specific isotype controls. All microscopic images shown are at a magnification of 100× with scale bar = 200 μm
harvested from the 293FT cells culture and pooled for 
transduction into activated CD3+ T-cells via spinoculation. 
A relatively higher number of T-cells expressing green 
fluorescence were observed when transduced with 
supernatants collected from 5.5 μg compared to 2.5 μg or 
4.0 μg of the CAR transfer plasmid.
DISCUSSION
The CD3 surface marker is expressed on all T-cells and is 
associated with TCR (Ahmadi et al. 2011). An approximate 
of 70-80% of human peripheral blood lymphocytes are 
composed of CD3+ T-cells whereas only 30% of the CD3+ 
T-cells is comprised of CD8+ T-cells (Rivkina et al. 2015; 
Sinon et al. 2013). The pre-selection of CD3+ T-cells to 
ensure a homogeneous T-cell population is vital, as the 
homogenous equilibrium of cells in patient’s blood can be 
interrupted by malignant proliferative changes generated 
by cancer (Rivkina et al. 2015). Deriving blood from 
cancer patients for an autologous immunotherapy without 
extensive pre-selection will affect the efficiency and might 
result in unwanted complications during in vivo clinical 
applications. Thus, for this purpose, we have proposed 
that selecting T-cells based on CD3+ T-cell marker is not 
only sufficient but superior to selecting T-cells at the sub-
population of CD8+. Selecting patient sample at CD3+ 
T-cells would overcome the challenge of limited cell 
availability and proliferative capability conferred by CD8+ 
T-cells. Furthermore, cancer immunotherapy is dependent 
on the ability of CD3+ T-cells to home and eradicate tumor 
cells in vivo (Bollard et al. 2012).
 Transduction of primary human T-cells poses a 
problem as T-cells are non-dividing quiescent cells in vitro 
(Zack et al. 2013). Multiple strategies can be adopted to 
increase the viral titer and transduction efficiency, including 
optimization of the transfer plasmid and viral particle 
concentrations and modifications to the culture conditions 
such as spinoculation (Cribbs et al. 2013). Lentiviral vectors 
are favored for advantageous traits such as the ability to 
transfer genes into both dividing and non-dividing T-cells; 
in contrast, retroviral methods typically can only be used 
to transfer genes into dividing cells (Cribbs et al. 2013). 
As non-activated T-cells are primarily non-dividing cells, 
lentivirus allows for more stable and long-term transduction 
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of cells with a lower tendency towards gene silencing, when 
compared to retroviruses (Shaw & Cornetta 2014).
 In the current study, isolated PBMCs were subjected 
to magnetic separation to generate a highly homogenous 
CD3+ T-cells population (Figure 2). The isolated CD3+ 
T-cells were activated and transduced with lentiviral 
particles encoding the CAR gene. Figure 5 shows a 
schematic representation of the complete experimental 
protocols employed in this study, including human T-cells 
isolation, activation, culture, transduction and ultimately 
determination of transduction efficiency via fluorescence 
microscopy. 
 Here, we demonstrated that activation of the isolated 
CD3+ T-cells with Dynabead-conjugated CD3/CD28 
human T-cell activator and interleukin-2 (IL-2) before 
transduction and optimization of the CAR transfer plasmid 
at 5.5 μg of concentration in a fast and efficient method 
via spinoculation could result in increased transduction 
efficiency. Higher transduction efficiency is vital for 
downstream applications to evaluate CAR-T cell targeting 
FIGURE 4. Phase contrast and fluorescence (GFP) imaging of 293FT cells and T-cells. 293FT cells were transfected with either control 
(non-transfection) or 2.5 μg, 4.0 μg and 5.5 μg of CAR transfer plasmid. The corresponding transduction of control (non-transduced), 
2.5 μg, 4.0 μg and 5.5 μg of CAR lentivirus particles into T-cells is also shown. Increased GFP expression was seen when higher 
concentrations of CAR transfer plasmid were added (5.5 μg). The increase in T-cells expressing GFP indicated a higher rate of transduction 
into T-cells and the successful expression of GFP. All microscopic images shown are at a magnification of 100× with scale bar = 200 μm
FIGURE 5. Schematic representation of the complete experimental protocols employed in this study. The protocols are schematically 
shown, including human T-cells isolation, activation, culture, transduction and ultimately determination of transduction 
efficiency via fluorescence microscopy. The CAR lentiviral particles generation is also portrayed
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of ERBB2-overexpressing cancer cell lines. This, in turn, 
is crucial for the downstream application of evaluating 
the apoptosis-inducing function of CAR-T-cells on ERBB2-
overexpressing cancer cell line. 
 CAR-T cells could mediate cytolysis predominantly 
by the action of granzyme-B and perforin (Chmielewski et 
al. 2013). Upon activation by a target cell via the binding 
of the anti-ERBB2 scFv segment on the CAR-T cells to the 
ERBB2 antigen on the tumor cells, the CAR-T cells trigger 
immune activity. CAR-T cells execute the exocytosis 
of secretory granules containing perforin and the pro-
apoptotic serine protease, granzyme B (De Saint Basile 
et al. 2010), which induces apoptosis by cleaving critical 
substrates in tumor cells (Chmielewski et al. 2013). Figure 
6 is a schematic representation of the apoptotic mechanism 
exerted by CAR-T-cells upon binding to ERBB2 antigens 
on a tumor cell. Following ligation, CAR-T cells release 
perforin and granzyme B to increase the secretion of pro-
inflammatory cytokines such as interferon-gamma (IFN-γ) 
and interleukin-2 (IL-2). 
CONCLUSION
The current study was able to optimize an efficient method 
for the transduction of the CAR gene specific for ERBB2 
antigen into human CD3+ T-cells via spinoculation. We 
overcame the challenges of transducing primary T-cells by 
selecting at CD3+ T-cell marker, activating the T-cells prior 
to transduction and increasing the CAR lentiviral transfer 
plasmid concentration. Future studies should determine 
the efficiency of specific targeting and killing mediated 
by the transduced CAR-T-cells upon co-culture with the 
ERBB2-overexpressing cancer cell line. 
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